CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 145 enrolled
Drug / intervention
cholecalciferol (vit D3)dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04117750
NCT04117750N/ACompleted
CompareCT.gov

Impact of Vitamin D Supplementation on the Cardiometabolic Status and Androgen Profile in Women With Polycystic Ovary Syndrome: Placebo-Controlled Clinical Trial

Zagazig University·interventional·Posted Oct 7, 2019·Updated Oct 8, 2019

In Brief

A clinical study evaluating cholecalciferol (vit D3) for Evaluations, Diagnostic Self and Treatment Adherence. Completed, enrolled 145 participants across 1 site.

Detailed Summary

Polycystic ovary syndrome (PCOS) is a heterogeneous disorder of reproductive, endocrine and metabolic functions. Vitamin D has an influence on metabolic and reproductive functions. This study was designed to explore the levels of free 25 hydroxy cholecalciferol \[25(OH) D\] in PCOS patients. We also aimed to clarify the impact of vitamin D supplementation on cardiometabolic status, androgen profile and clinical features of PCOS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEvaluations, Diagnostic Self, Treatment Adherence
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedOct 7, 2019
Enrollment StartNov 1, 2017
Primary CompletionApr 1, 2018
Study CompletionJul 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.7 years ago

Interventions

cholecalciferol (vit D3)dietary

42,000 IU oral vitamin D per week and 500 mg calcium carbonate